FDA panel narrowly backs compounding of five peptides

A federal advisory panel has narrowly voted to recommend easing restrictions on several popular synthetic peptides, a move that would allow specialized pharmacies to compound the substances despite significant safety concerns raised by government scientists. The two-day meeting of the Food and Drug Administration’s Pharmacy Compounding Advisory Committee concluded on July 24, 2026, with votes to recommend allowing compounding for five of the seven peptides under review.

On July 23, the panel voted 8-6 to recommend adding BPC-157, KPV, TB-500, and MOTS-c to a list of substances that can be compounded by pharmacies for individual patients with a prescription. The following day, the committee voted 7-4 to recommend adding epitalon. However, it voted 6-7 against recommending emideltide. A vote on the seventh peptide, Semax, was also scheduled for July 24, but the outcome was not specified in the latest reports. The panel's recommendations are advisory, and the FDA will make the final regulatory decision.

Throughout the meetings, FDA career scientists presented detailed analyses urging against the move, citing a fundamental lack of human clinical trial data to establish safety and...